how long has glp-1 been around medications are transforming diabetes and weight loss treatment Disruptive Innovations Shaping the GLP-1

According to the Summary of Product Characteristics (SmPC) for these medications, headache is classified as very common (affecting more than 1 in 10 people) with weight-management doses of GLP-1 receptor agonists such as Wegovy (semaglutide 2.4 mg) and Saxenda (liraglutide 3 mg)

Snchez-Garrido MA, Brandt SJ, Clemmensen C, Mller TD, DiMarchi RD, Tschp MH, et al

So blood tests, because we know the research is clear that if it is sub-therapeutic levels, even if she's not having hot flashes, [00:40:00] we shouldn't be expecting the full metabolic benefit

Some people experience genuine food aversion during the first few weeks, where the thought of eating feels unpleasant

Additional information from this trial is included in subsequent sections below, when relevant